Clinical Trials Browser

Phase 1/2 × Carcinoma, Hepatocellular × linrodostat × Clear all

NCT03695250 2023-08-22

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Phase 1/2 Terminated

8 enrolled 11 charts

Gastrointestinal

Carcinoma, Hepatocellular